Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 5/20 | 0.77 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.77 |
| ▸ | REN | P00797 | 5/20 | 0.65 |
| ▸ | NPY2R | P49146 | 7/20 | 0.64 |
| ▸ | NPY4R | P50391 | 7/20 | 0.64 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.64 |
| ▸ | NPY1R | P25929 | 5/20 | 0.64 |
| ▸ | TFPI | P10646 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Angiotensin Ii SCHEMBL13232382 | 0.95 | AGTR2 (0.84) | AGTR2AGTR1REN | |
| Angiotensin Ii SCHEMBL1189 | 0.95 | AGTR2 (0.84) | AGTR2AGTR1REN | |
| Angiotensin Ii SCHEMBL2566771 | 0.95 | AGTR2 (0.84) | AGTR2AGTR1REN | |
| SCHEMBL32930844 | 0.95 | AGTR1 (0.70) | AGTR2AGTR1RENNPY2RNPY4R | |
| Angiotensin Ii SCHEMBL3465991 | 0.95 | AGTR2 (0.83) | AGTR2AGTR1REN | |
| Angiotensin Ii SCHEMBL14990505 | 0.95 | AGTR2 (0.83) | AGTR2AGTR1REN | |
| Angiotensin Ii SCHEMBL21267957 | 0.95 | AGTR2 (0.83) | AGTR2AGTR1REN | |
| Angiotensin Ii SCHEMBL1585377 | 0.94 | AGTR2 (0.83) | AGTR2AGTR1REN | |
| Angiotensin Ii SCHEMBL2183118 | 0.94 | AGTR2 (0.83) | AGTR2AGTR1REN | |
| Angiotensin Ii SCHEMBL8898391 | 0.94 | AGTR2 (0.83) | AGTR2AGTR1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4039249-B1 | REMOVAL OF SERINE PROTEASES BY TREATMENT WITH FINELY DIVIDED SILICON DIOXIDE | TAKEDA PHARMACEUTICALS CO (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-12545703-B2 | Method to produce an immunoglobulin preparation with improved yield | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-02-10 | — | — | US | disclosed |
| US-20240117009-A1 | REMOVAL OF SERINE PROTEASES BY TREATMENT WITH FINELY DIVIDED SILICON DIOXIDE | TAKEDA PHARMACEUTICALS CO (JP) | 2024-04-11 | — | — | US | disclosed |
| US-11891431-B2 | Removal of serine proteases by treatment with finely divided silicon dioxide | Takeda Pharm Limited ceutical Company Limited (JP) | 2024-02-06 | — | — | US | disclosed |
| EP-2803349-B1 | Method for preparing an enriched IgG composition from plasma | TAKEDA PHARMACEUTICALS CO (JP) | 2023-09-27 | — | — | EP | disclosed |
| US-20230142480-A1 | A METHOD TO PRODUCE AN IMMUNOGLOBULIN PREPARATION FROM C-1 INHIBITOR DEPLETED PLASMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | disclosed |
| EP-4126930-A1 | A METHOD TO PRODUCE AN IMMUNOGLOBULIN PREPARATION FROM C-1 INHIBITOR DEPLETED PLASMA | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| EP-4039249-A1 | REMOVAL OF SERINE PROTEASES BY TREATMENT WITH FINELY DIVIDED SILICON DIOXIDE | Baxalta GmbH (CH) | 2022-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545703-B2 | Method to produce an immunoglobulin preparation with improved yield | FCGR3B, FCGR2A, IGLV6-57 | AGTR2 4560/4885AGTR1 4505/4885REN 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.